Evren Alici

Publications
Grants
CV
Public outreach and news

Articles

Article: NATURE BIOMEDICAL ENGINEERING. 2024;8(11):1453-1468
Antibody-displaying extracellular vesicles for targeted cancer therapy
Wiklander OPB; Mamand DR; Mohammad DK; Zheng W; Jawad Wiklander R; Sych T; Zickler AM; Liang X; Sharma H; Lavado A; Bost J; Roudi S; Corso G; Lennaard AJ; Abedi-Valugerdi M; Maeger I; Alici E; Sezgin E; Nordin JZ; Gupta D; Goergens A; EL Andaloussi S
Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickstrom SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Article: JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH. 2024;43(1):13
Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease
Neo SY; Oliveira MMS; Tong L; Chen Y; Chen Z; Cismas S; Burduli N; Malmerfelt A; Teo JKH; Lam K-P; Alici E; Girnita L; Wagner AK; Westerberg LS; Lundqvist A
Article: ONCOIMMUNOLOGY. 2023;12(1):2233402
Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8⁺ T cells towards the center of human lung tumors
Brownlie D; von Kries A; Valenzano G; Wild N; Yilmaz E; Safholm J; Al-Ameri M; Alici E; Ljunggren H-G; Schliemann I; Aricak O; de Flon FH; Michaelsson J; Marquardt N
Article: CANCER MEDICINE. 2023;12(22):20736-20744
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Nahi H; Afram G; Uttervall K; Lockmer S; Tatting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: NATURE COMMUNICATIONS. 2023;14(1):6035
Modulation of lytic molecules restrain serial killing in γδ T lymphocytes
Sandoz PA; Kuhnigk K; Szabo EK; Thunberg S; Erikson E; Sandstroem N; Verron Q; Brech A; Watzl C; Wagner AK; Alici E; Malmberg K-J; Uhlin M; Oenfelt B
Article: CYTOTHERAPY. 2023;25(7):763-772
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren H-G; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Journal article: CYTOTHERAPY. 2023;25(6):s13-s14
13 Tissue Engineering: GENERATION OF UNIVERSAL CELLULAR GRAFTS UTILIZING SIGNALING-DEFICIENT MEMBRANE-BOUND CD45 ENGAGERS
Hussain A; Mohammad DK; Karvouni M; Hållstrand C; Gilljam M; Wagner AK; Ljunggren H; Alici E
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: SCIENCE SIGNALING. 2023;16(780):eabq0752
SHP-1 localization to the activating immune synapse promotes NK cell tolerance in MHC class I deficiency
Schmied L; Luu TT; Sondergaard JN; Hald SH; Meinke S; Mohammad DK; Singh SB; Mayer C; Casoni GP; Chrobok M; Schlums H; Rota G; Truong HM; Westerberg LS; Guarda G; Alici E; Wagner AK; Kadri N; Bryceson YT; Saeed MB; Hoglund P
Article: METHODS IN CELL BIOLOGY. 2023;178:43-61
A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids.
Schwietzer YA; Susek KH; Chen Z; Alici E; Wagner AK
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754
Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(11):e005577
Adaptive single-KIR⁺NKG2C⁺ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikstroem K; Blomberg P; Alici E; Felices M; oenfelt B; Hoeglund P; Valamehr B; Ljunggren H-G; Bjoerklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg K-J; Sohlberg E
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(10):e005308
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
Neo SY; Jing X; Tong L; Tong D; Gao J; Chen Z; De Los Santos MC; Burduli N; Ferreira SDS; Wagner AK; Alici E; Rolny C; Cao Y; Lundqvist A
Article: CURRENT ISSUES IN MOLECULAR BIOLOGY. 2022;44(9):3859-3871
Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells
Rasul KH; Hussain A; Reilly H; Karvouni M; Dahlberg CIM; Al-Attar MS; Wagner AK; Alici E; Mohammad DK
Journal article: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:s41-s41a
P-010: Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Journal article: HEMASPHERE. 2022;6(Suppl):1318-1319
P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB‐BASED ANTI‐ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
Meinke S; Kadri N; Bi S; Bostancioglu B; Markey C; Breitmeyer JB; Hussain A; Krishnan R; Kaufmann GF; Alici E
Journal article: HEMASPHERE. 2022;6(Suppl ):1326-1327
P1443: AUTOLOGOUS NK CELLS AS CONSOLIDATION AFTER FRONT-LINE STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: A LONG-TERM FOLLOW-UP
Lund J; Nahi H; Meinke S; Holmqvist P-H; Ljunggren H-G; Aschan J; Alici E
Article: CELL REPORTS MEDICINE. 2022;3(2):100508
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi H; Chrobok M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Blomberg P; Holmqvist P-H; Walther-Jallow L; Mellstrom K; Liwing J; Gustafsson C; Mansson R; Klimkowska M; Gahrton G; Lund J; Ljungman P; Ljunggren H-G; Alici E
Article: MOLECULAR MEDICINE. 2022;28(1):20
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-G
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Mansson R; Wagner AK; Alici E
Article: LIFE SCIENCE ALLIANCE. 2021;4(4):e202000723
Short-term IL-15 priming leaves a long-lasting signalling imprint in mouse NK cells independently of a metabolic switch
Luu TT; Schmied L; Nguyen N-A; Wiel C; Meinke S; Mohammad DK; Bergo M; Alici E; Kadri N; Ganesan S; Hoglund P
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;106(4):546-554
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Afram G; Susek KH; Uttervall K; Wersall JD; Wagner AK; Luong V; Lund J; Gahrton G; Alici E; Nahi H
Article: EMBO REPORTS. 2021;22(3):e51329
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25⁺/CD54⁺ NK cells
Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson P-J; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(1):23-30
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
Gran C; Liwing J; Wagner AK; Verhoek A; Gezin A; Alici E; Nahi H
Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2021;9:612714
The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function
Abomaray F; Wagner AK; Chrobok M; Ekblad-Nordberg A; Gidlof S; Alici E; Gotherstrom C
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;105(6):751-754
Outcome of COVID-19 in multiple myeloma patients in relation to treatment
Susek KH; Gran C; Ljunggren H-G; Alici E; Nahi H
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(10):5508-5522
Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;105(2):196-202
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment
Afram G; Gran C; Borg Bruchfeld J; Wagner AK; Hussain A; Alici E; Nahi H
Article: STEM CELL REPORTS. 2020;14(4):648-662
Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II
Petrus-Reurer S; Winblad N; Kumar P; Gorchs L; Chrobok M; KathleenWagner A; Bartuma H; Lardner E; Aronsson M; Reyes AP; Andre H; Alici E; Kaipe H; Kvanta A; Lanner F
Journal article: CANCER IMMUNOLOGY RESEARCH. 2020;8(4_Supplement):a55
Abstract A55: Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+ sarcomas and other malignancies
Sayitoglu EC; Chrobok M; Georgoudaki A-M; Josey BJ; Hartman M; Vallabhaneni E; Herekar R; Bergeron S; Krueger R; Sutlu T; Alici E; Temple HT; Duru AD
Journal article: CANCER IMMUNOLOGY RESEARCH. 2020;8(4_Supplement):a21
Abstract A21: Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer
Parlar A; Sayitoglu EC; Pamukcu C; Georgoudaki A-M; Ozkazanc D; Aras M; Josey B; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Sutlu T; Duru AD
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(3):1185-1198
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:40
Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
Sayitoglu EC; Georgoudaki A-M; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(6):588-596
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran C; Uttervall K; Bruchfeld JB; Wallblom A; Alici E; Gahrton G; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(3):247-254
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Uttervall K; Bruchfeld JB; Gran C; Walinder G; Mansson R; Lund J; Gahrton G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2019;49(8):1278-1290
Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki A-M; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Article: CYTOTHERAPY. 2019;21(3):315-326
Characterization of human natural killer cells for therapeutic use mas
Wagner AK; Alici E; Lowdell MW
Article: CANCERS. 2019;11(1):E69-69
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
Chrobok M; Dahlberg CIM; Sayitoglu EC; Beljanski V; Nahi H; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Article: PLOS ONE. 2019;14(2):e0211927
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Nahi H; Chrobok M; Gran C; Lund J; Gruber A; Gahrton G; Ljungman P; Wagner AK; Alici E
Article: CANCER MEDICINE. 2018;7(6):2256-2268
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frolund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist U-H; Nahi H
Journal article: JOURNAL OF IMMUNOLOGY. 2018;200(1_Supplement):169.19
Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells
Sayitoglu EC; Ozkazanc D; Sarac A; Parlar A; Alici E; Erman B; Duru AD; Sutlu T
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;100(4):386-388
Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients
Gran C; Gahrton G; Alici E; Nahi H
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2018;81(1):183-193
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Article: BLOOD ADVANCES. 2017;1(10):619-623
Direct evidence for a polygenic etiology in familial multiple myeloma
Halvarsson B-M; Wihlborg A-K; Ali M; Lemonakis K; Johnsson E; Niroula A; Cibulskis C; Weinhold N; Foersti A; Alici E; Langer C; Pfreundschuh M; Goldschmidt H; Mellqvist U-H; Turesson I; Waage A; Hemminki K; Golub T; Nahi H; Gullberg U; Hansson M; Nilsson B
Article: HUMAN GENE THERAPY METHODS. 2017;28(2):78-90
Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration
Bandeira VS; Tomas HA; Alici E; Carrondo MJT; Coroadinha AS
Article: MOLECULAR NEUROBIOLOGY. 2017;54(2):874-887
Perforin Promotes Amyloid Beta Internalisation in Neurons
Lana E; Khanbolouki M; Degavre C; Samuelsson E-B; Akesson E; Winblad B; Alici E; Lithner CU; Behbahani H
Article: SCIENTIFIC REPORTS. 2016;6:37996
Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+dendritic cells
Thuy TL; Ganesan S; Wagner AK; Sarhan D; Meinke S; Garbi N; Haemmerling G; Alici E; Karre K; Chambers BJ; Hoglund P; Kadri N
Article: STEM CELL REPORTS. 2016;6(4):607-617
Wnt/β-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells
Mansson-Broberg A; Rodin S; Bulatovic I; Ibarra C; Lofling M; Genead R; Wardell E; Felldin U; Granath C; Alici E; Le Blanc K; Smith CIE; Salasova A; Westgren M; Sundstrom E; Uhlen P; Arenas E; Sylven C; Tryggvason K; Corbascio M; Simonson OE; Osterholm C; Grinnemo K-H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;96(1):46-54
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Nahi H; Vatsveen TK; Lund J; Heeg BMS; Preiss B; Alici E; Moller MB; Wader KF; Moller HEH; Groseth LA; Ostergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Article: PLOS ONE. 2015;10(9):e0138248
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Article: HUMAN IMMUNOLOGY. 2014;75(8):777-784
Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia
da Silva RF; Petta CA; Derchain SF; Alici E; Guimaraes F
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(5):684-693
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Kviele HH; Johansson P; Lauri B; Mellqvist U-H; Swedin A; Svensson M; Nasman P; Alici E; Gahrton G; Aschan J; Nahi H
Article: STEM CELL RESEARCH AND THERAPY. 2014;5(1):9
Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data
Martins JP; Santos JM; de Almeida JM; Filipe MA; Teixeira de Almeida MV; Paiva Almeida SC; Agua-Doce A; Varela A; Gilljam M; Stellan B; Pohl S; Dittmar K; Lindenmaier W; Alici E; Graca L; Cruz PE; Cruz HJ; Barcia RN
Article: PLOS ONE. 2014;9(9):e107712
Characterization of Stem-Like Cells in Mucoepidermoid Tracheal Paediatric Tumor
Lim ML; Ooi BNS; Jungebluth P; Sjoqvist S; Hultman I; Lemon G; Gustafsson Y; Asmundsson J; Baiguera S; Douagi I; Gilevich I; Popova A; Haag JC; Rodriguez AB; Lim J; Lieden A; Nordenskjold M; Alici E; Baker D; Unger C; Luedde T; Vassiliev I; Inzunza J; Ahrlund-Richter L; Macchiarini P
Article: PLOS ONE. 2014;9(7):e101819
The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(1):19-25
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis
Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Article: HUMAN GENE THERAPY. 2012;23(10):1090-1100
Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
Sutlu T; Nystrom S; Gilljam M; Stellan B; Applequist SE; Alici E
Article: CURRENT OPINION IN MOLECULAR THERAPEUTICS. 2010;12(6):724-733
IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers
Alici E
Article: CYTOTHERAPY. 2010;12(8):1044-1055
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Article: LEUKEMIA RESEARCH. 2010;34(12):1627-1629
Constitutional inv(3) in myelodysplastic syndromes
Gahrton C; Nahi H; Jansson M; Wallblom A; Alici E; Sutlu T; Samuelsson J; Gahrton G
Article: HUMAN GENE THERAPY. 2010;21(8):929-941
TK.007: A Novel, Codon-Optimized HSVtk(A168H) Mutant for Suicide Gene Therapy
Preuss E; Treschow A; Newrzela S; Bruecher D; Weber K; Felldin U; Alici E; Gahrton G; von Laer D; Dilber MS; Fehse B
Article: IMMUNOTHERAPY. 2009;1(5):753-764
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Bjorkstrom NK; Soderdahl G; Cederlund K; Kimby E; Aschan J; Ringden O; Ljunggren H-G; Dilber MS
Article: ONCOLOGY REPORTS. 2009;22(1):137-142
Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation
Paul E; Sutlu T; Deneberg S; Alici E; Bjorkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Article: METHODS IN MOLECULAR BIOLOGY. 2009;506:127-137
Retroviral gene transfer into primary human natural killer cells.
Alici E; Sutlu T; Sirac Dilber M
Journal article: BLOOD. 2008;112(11):5153
The Prognostic Significance of 8p21 Deletion in Multiple Myeloma
Nahi H; Sutlu T; Alici E; Gahrton G
Journal article: BLOOD. 2008;112(11):5148
Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation
Paul E; Sutlu T; Alici E; Gahrton G; Nahi H
Article: BLOOD. 2008;111(6):3155-3162
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Alici E; Sutlu T; Boejrkstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(12):1839-1846
Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
Alici E; Konstantinidis KV; Sutlu T; Aints A; Gahrton G; Ljunggren H-G; Dilber MS
Article: CANCER GENE THERAPY. 2007;14(3):227-232
Long-term follow-up of gene-marked CD34⁺ cells after autologous stem cell transplantation for multiple myeloma
Alici E; Bjorkstrand B; Treschow A; Aints A; Smith CIE; Gahrton G; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2005;33(11):1320-1328
Efficient gene transfer into primary human natural killer cells by retroviral transduction
Guven H; Konstantinidis KV; Alici E; Aints A; Abedi-Valugerdi M; Christensson B; Ljunggren HG; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2005;33(2):159-164
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
Konstantinidis KV; Alici E; Aints A; Christensson B; Ljunggren HG; Dilber MS
Article: EXPERIMENTAL HEMATOLOGY. 2004;32(11):1064-1072
Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: Establishment of a new syngeneic murine model of multiple myeloma
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Journal article: ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY. 2001;121(1-2):65-66
Effect of preoperative chemotherapy on the outcome of surgical treatment of vertebral tuberculosis:: retrospective analysis of 434 cases
Alici E; Akçali Ö; Tatari H; Günal I
Journal article: SPINE. 1996;21(17):1991-1995
Detection of Mycobacterium tuberculosis in formaldehyde solution-fixed, paraffin-embedded tissue by polymerase chain reaction in Pott's disease
Berk RH; Yazici M; Atabey N; Ozdamar OS; Pabuccuoglu U; Alici E
Show more

All other publications

Meeting abstract: BLOOD. 2023;142:1960
A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk
Kashif M; Zhou Y; Luong V; Uttervall K; Gahrton G; Nahi H; Alici E; Lund J
Conference publication: 2023;:a1174
1067 A three stage immune targeted immuno-cytokine platform that delivers inflammatory signals to the tumor microenvironment
Rabinovich B; Zhou X; Takimoto J; Khanna N; Yoon S; Alici E
Letter: CANCER COMMUNICATIONS. 2023;43(7):855-859
Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1
Tong L; Kremer V; Neo SY; Liu Y; Chen Y; Wagner AK; Yang Y; Chen Z; Seitz C; Tobin NP; Ligtenberg MA; Alici E; Chen X; Haglund F; Seliger B; Harmenberg U; Colon E; Plogell A-HS; Liu LL; Lundqvist A
Preprint: RESEARCH SQUARE. 2023
Modulation of lytic molecules restrain serial killing in γδ T lymphocytes
Onfelt B; Sandoz P; Kuhnigk K; Szabo E; Thunberg S; Erikson E; Sandström N; Verron Q; Brech A; Watzl C; Wagner A; Alici E; Malmberg K-J; Uhlin M
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225
Response to Caravita di Toritto and Rago
Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Conference publication: CYTOTHERAPY. 2023;25(6):S13-S14
GENERATION OF UNIVERSAL CELLULAR GRAFTS UTILIZING SIGNALING-DEFICIENT MEMBRANE-BOUND CD45 ENGAGERS
Hussain A; Mohammad DK; Karvouni M; Hallstrand C; Gilljam M; Wagner AK; Ljunggren H; Alici E
Conference publication: BLOOD. 2022;140:12440-12441
HSV1716 Infects Multiple Myeloma Cells and Leads to CD138 Downregulation
Susek KH; Flore VN; Karvouni M; Meinke S; Conner J; Powers C; Allen R; Wagner AK; Alici E
Conference publication: 2022;:a1110
1068 A ROR1 specific CD3 bispecific T-cell engager engineered for solid tumors with an expanded therapeutic window
Rabinovich B; Zhou X; Takimoto J; Song P; Alici E; Khanna N
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:s46-s47
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Preprint: BIORXIV. 2022
Control of NK cell tolerance in MHC class I-deficiency by regulated SHP-1 localization to the activating immune synapse
Schmied L; Luu T; Søndergaard J; Meinke S; Mohammad D; Singh S; Mayer C; Casoni G; Chrobok M; Schlums H; Rota G; Truong H; Westerberg L; Guarda G; Alici E; Wagner A; Kadri N; Bryceson Y; Saeed M; Höglund P
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:S46-S47
PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer
Susek K; Schwietzer Y; Karvouni M; Gilljam M; Keszei M; Baloch AH; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner A; Alici E
Review: FRONTIERS IN IMMUNOLOGY. 2022;13:825979
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
Karvouni M; Vidal-Manrique M; Lundqvist A; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2022;22:S41
Exploring the feasibility of CD38-targeting CAR-NK therapy for multiple myeloma by harnessing features of cytokine-expanded NK cells
Karvouni M; Vidal-Manrique M; Susek K; Wagner A; Kashif M; Gilljam M; Baloch AH; Lundqvist A; Alici E
Meeting abstract: BLOOD. 2021;138:4796
CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion
Nahi H; Chrobook M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Walther-Jallow L; Liwing J; Klimkowska M; Gahrton G; Ljungman P; Ljunggren H-G; Alici E
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy
Lockmer S; Uttervall K; Kashif M; Svard C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Editorial comment: CLINICAL CHEMISTRY. 2021;67(10):1309-1311
Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma
Kashif M; Alici E; Nahi H
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(3):E63-E65
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2021;94(6)
SHP-1 expression and localization are associated with functional education of murine natural killer cells
Luu T; Schmied L; Sondergaard JN; Saeed MB; Meinke S; Mohammad D; Casoni GP; Schlums H; Truong HM; Westerberg L; Bryceson Y; Alici E; Wagner AK; Kadri N; Hoglund P
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2020;8(4):49-50
Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Pamukcu C; Georgoudaki A-M; Ozkazanc D; Aras M; Josey B; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Sutlu T; Duru AD
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2020;8(4):64-65
Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+sarcomas and other malignancies.
Sayitoglu EC; Chrobok M; Georgoudaki A-M; Josey BJ; Hartman M; Vallabhaneni E; Herekar R; Bergeron S; Krueger R; Sutlu T; Alici E; Temple HT; Duru AD
Conference publication: BLOOD. 2019;134:1848
Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples
Karvouni M; Zhou H; Kathleen A; Ma Q; Baloch AH; Zhu T; Zhang H; Gilljam M; Lundqvist A; Kaufmann GF; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):E169
Combination of herpes-simplex based oncolytic viruses (HSV-OV) with natural killer (NK) cells in Multiple Myeloma
Susek KH; Meinke S; Wagner AK; Ljunggren H-G; Alici E
Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):E163-E164
A novel antiCD38-CAR construct increases the in vitro responsiveness of NK cells against Multiple Myeloma cells
Karvouni M; Wagner AK; Baloch AH; Gilljam M; Lundqvist A; Alici E
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):E158
Reinstating anti-tumor activity of Natural Killer cells
Caliskan C; Chrobok M; Wagner AK; Bruchfeld JB; Nahi H; Alici E
Meeting abstract: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2019;19(10):E170
Novel RNA construct increases cytotoxic proteins in lymphocytes and leads to prolonged survival in an experimental syngeneic immunocompetent Multiple Myeloma model
Wagner AK; Baloch AH; Chrobok M; Dahlberg C; Gahrton G; Nahi H; Ljunggren H-G; Alici E
Preprint: SSRN ELECTRONIC JOURNAL. 2019
A Brief IL-15 Pulse Results in JAK3-Dependent Phosphorylation of ITAM-Associated Signaling Molecules and a Long-Lasting Priming Imprint in Mouse NK Cells
Luu TT; Nguyen N-A; Ganesan S; Meinke S; Kadri N; Alici E; Höglund P
Meeting abstract: BLOOD. 2018;132:195
Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS
Sohlberg E; Haroun-Izquierdo A; Bjorklund AT; Cooley S; Wiiger MT; Goodridge P; Hoel HJ; Pfefferle A; Chrobook M; Kremer V; Hellstrom-Lindberg E; Ask EH; Pontus B; Valamehr B; Guldevall K; van Ooijen H; Onfelt B; Alici E; Ljunggren H-G; Miller JS; Malmberg K-J
Conference publication: JOURNAL OF IMMUNOLOGY. 2018;200(1)
Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells
Sayitoglu EC; Ozkazanc D; Sarac A; Parlar A; Alici E; Erman B; Duru AD; Sutlu T
Conference publication: EUROPEAN JOURNAL OF HUMAN GENETICS. 2018;26:558
Direct evidence for a polygenic etiology in familial multiple myeloma
Halvarsson B; Wihlborg A; Ali M; Lemonakis K; Johnsson E; Niroula A; Cibulskis C; Weinhold N; Foersti A; Alici E; Langer C; Pfreundschuh M; Goldschmidt H; Mellqvist U; Turesson I; Waage A; Hemminki K; Golub T; Nahi H; Gullberg U; Hansson M; Nilsson B
Conference publication: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE. 2018;59(9)
In vitro and in vivo immunologic characterization of human embryonic stem cell-derived retinal pigment epithelial cells
Petrus-Reurer S; Gorchs L; Chrobok M; Wagner AK; Lardner E; Bartuma H; Aronsson M; Westman S; Alici E; Kaipe H; Lanner F; Kvanta AP
Review: FRONTIERS IN IMMUNOLOGY. 2018;9:2159
The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment
Susek KH; Karvouni M; Alici E; Lundqvist A
Meeting abstract: CANCER RESEARCH. 2017;77:5030
The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Nahi H; Lotfi K
Conference publication: HUMAN GENE THERAPY. 2017;28(12):A31-A32
Engineering antigen-specific NK cells via TCR gene transfer: A novel source for adoptive immunotherapy
Parlar A; Pamukcu C; Ozkazanc D; Aras M; Dahlberg C; Chrobok M; Zahedimaram P; Ikromzoda L; Sayitoglu EC; Alici E; Erman B; Duru AD; Sutlu T
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):348
Optimized genetic modification of primary human NK cells
Wagner AK; Chrobok M; Hussain A; Gilljam M; Dahlberg CIM; Sutlu T; Duru AD; Nahi H; Lundqvist A; Ljunggren H-G; Alici E
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):295
Reactive oxygen species are linked with general phosphorylation status and functional education of natural killer cells
Thuy TL; Vignesh S; Wagner AK; Chrobok M; Schlums H; Tornmalm J; Kadri N; Meinke S; Widengren J; Bryceson Y; Alici E; Johannsson S; Hoglund P
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):295
Interleukin-15 primes natural killer cell functions through proximal crosstalk with activating receptors
Thuy TL; Ngoc AN; Ganesan S; Meinke S; Wagner AK; Chrobok M; Alici E; Hoglund P
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):342
Adaption of NK-92 cells to serum-free culture with inherent anti-tumor response: NK-92 cells stand strong in a serum-free milieu
Chrobok M; Dahlberg CIM; Sayitoglu C; Nahi H; Sarhan D; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(3):473-477
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H
Review: ONCOIMMUNOLOGY. 2016;5(4):e1115178
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Koehl U; Kalberer C; Spanholtz J; Lee DA; Miller JS; Cooley S; Lowdell M; Uharek L; Klingemann H; Curti A; Leung W; Alici E
Conference publication: BLOOD. 2015;126(23):5366
Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach
Lund J; Alici E; Chrobok M; Gruber A; Ahmadi T; Khan I; Nahi H
Conference publication: BLOOD. 2015;126(23):3047
The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex
Lund J; Karstorp S; Alici E; Gruber A; Lauri B; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Conny C; Waage A; Gimsing P; Vangsted AJ; Frolund UC; Hardling M; Mellqvist U-H; Nahi H
Conference publication: HUMAN GENE THERAPY. 2015;26(10):A6
Innate immune sensors restrict lentiviral gene delivery to human natural killer cells: novel perspectives on the use of viral vectors
Sayitoglu EC; Duru AD; Chrobok M; Chiang C; Parlar A; Senturk GH; Erman B; Alici E; Sutlu T
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S17
Multiple Myeloma patients with del(8)(p21) are more resistant to Bortezomib treatment
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Review: FRONTIERS IN IMMUNOLOGY. 2015;6:605
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
Dahlberg CIM; Sarhan D; Chrobok M; Duru AD; Alici E
Conference publication: HUMAN GENE THERAPY. 2013;24(12):A97-A98
Comparison of different strategies for the establishment of retroviral cell lines: random vs. targeted integration
Bandeira VS; Tomas H; Alici E; Alves PM; Carrondo M; Coroadinha AS
Conference publication: HAEMATOLOGICA. 2013;98:326
MP VS MPT IN FIRST TO FOURTH LINE OF TREATMENT IN MULTIPLE MYELOMA PATIENTS
Lund J; Uttervall K; Liwing J; Aschan J; Alici E; Holmberg E; Nahi H
Conference publication: HAEMATOLOGICA. 2013;98:326-327
CAN NOVEL AGENTS OVERCOME THE NEGATIVE PROGNOSTIC IMPACT OF RENAL IMPAIRMENT IN MULTIPLE MYELOMA? - A POPULATION BASED STUDY INCLUDING 1538 PATIENTS
Uttervall K; Lund J; Liwing J; Holmberg E; Alici E; Aschan J; Nahi H
Letter: MEDICAL ONCOLOGY. 2013;30(2):569
In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidene et al
Sutlu T; Alici E; Gahrton G; Nahi H
Book chapter: THE CLINIBOOK. 2012;p. 187-193
A4-2 Ex-vivo expansion of human mesenchymal stem cells
Cruz PE; Cruz HJS; Bárcia RN; Santos JM; Pohl S; Gilljam M; Dittmar KEJ; Lindenmaier W; Alici E
Book chapter: THE CLINIBOOK. 2012;p. 201-207
A4-4 Genetically modified NK cells for cancer treatment: facts and visions
Alici E; Gahrton G
Conference publication: HAEMATOLOGICA. 2012;97:610
BORTEZOMIB, RESPONSE AND RETREATMENT IN 1ST, 2ND, 3RD AND 4TH LINE OF TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA
Andreasson A; Uttervall K; Liwing J; Alici E; Nasman P; Aschan J; Nahi H
Conference publication: HUMAN GENE THERAPY. 2012;23(10):A151
Enhancement of lentiviral transduction efficiency by inhibition of intracellular anti-viral defense mechanisms
Sutlu T; Nystrom S; Gilljam M; Stellan B; Applequist SE; Alici E
Letter: CYTOTHERAPY. 2011;13(6):767-768
Ex vivo expansion of natural killer cells: a question of function
Sutlu T; Alici E
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(2):137-147
Clinical impact of chromosomal aberrations in multiple myeloma
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
Review: CURRENT GENE THERAPY. 2010;10(6):508-515
GMP Facilities for Manufacturing of Advanced Therapy Medicinal Products for Clinical Trials: An Overview for Clinical Researchers
Alici E; Blomberg P
Review: IMMUNOTHERAPY. 2010;2(4):521-537
Suicide gene therapy for graft-versus-host disease
Georgoudaki A-M; Sutlu T; Alici E
Conference publication: HUMAN GENE THERAPY. 2010;21(10):1416
Expansion of NK cells for cancer immunotherapy: from process optimization to clinical evaluation
Sutlu T; Gahrton G; Alici E
Conference publication: BONE MARROW TRANSPLANTATION. 2010;45:S301
Superior performance of the novel suicide gene TK.007 in adoptive immunotherapy models both in vitro and in vivo
Preuss E; Treschow A; Newrzela S; Bruecher D; Weber K; Otte J; Felldin U; Alici E; von Laer D; Dilber S; Fehse B
Review: JOURNAL OF INTERNAL MEDICINE. 2009;266(2):154-181
Natural killer cell-based immunotherapy in cancer: current insights and future prospects
Sutlu T; Alici E
Conference publication: HUMAN GENE THERAPY. 2009;20(11):1464
The novel HSVtk mutant TK.007 shows superior performance both in vitro and in vivo
Preuss E; Treschow A; Newrzela S; Bruecher D; Weber K; Otte J; Felldin U; Alici E; von Laer D; Dilber S; Fehse B
Conference publication: MOLECULAR THERAPY. 2009;17:S223
A Novel, Codon-Optimised HSVtk(A168H) Mutant for Suicide Gene Therapy
Preuss E; Treschow A; Otte J; Bruecher D; Felldin U; Alici E; Dilber S; Fehse B
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(2):266-268
The prognostic significance of 8p21 deletion in multiple myeloma
Sutlu T; Alici E; Jansson M; Wallblom A; Dilber MS; Gahrton G; Nahi H
Published conference paper: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(10):1541-1552
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg K-J; Bryceson YT; Carlsten M; Andersson S; Bjorklund A; Bjorkstrom NK; Baumann BC; Fauriat C; Alici E; Dilber MS; Ljunggren H-G
Conference publication: HUMAN GENE THERAPY. 2008;19(10):1183
Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma
Alici E; Sutlu T; Bjokstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Conference publication: HUMAN GENE THERAPY. 2008;19(10):1141
Optimal ouaselect and thymidine kinase functionality in T cells is defined by the transgene cassette
Treschow A; Schambach A; Felldin U; Alici E; Gahrton G; Fehse B; Baum C; Dilber MS
Conference publication: HUMAN GENE THERAPY. 2007;18(10):992-993
Natural killer cells kill syngeneic myeloma cells in C57Bl/KaLwRij upon adoptive transfer
Alici E; Sutlu T; Gahrton G; Dilber S
Thesis / dissertation: 2006
Therapeutic potential of natural killer cells in multiple myeloma
Alici, Evren
Show more

Grants

Use of ex vivo expanded natural killer cells as a treatment strategy for hematological malignancies with special emphasis on multiple myeloma
Swedish Research Council
1 January 2012 - 31 December 2014

Employments

Principal Researcher, Department of Medicine, Huddinge, Karolinska Institutet, 2022-

Degrees and Education

Docent, Karolinska Institutet, 2021
Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2006

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI